Navigation Links
Stopping Blood Thinners Raises Stroke Risk for Patients With Irregular Heartbeat
Date:4/25/2012

By Steven Reinberg
HealthDay Reporter

WEDNESDAY, April 25 (HealthDay News) -- When patients with atrial fibrillation stop taking anti-clotting drugs, their stroke risk goes up quickly, new research finds.

That risk increases about the same whether they are taking warfarin or a newer, more expensive drug, Xarelto (rivaroxaban).

Atrial fibrillation is an abnormal heart rhythm in which the upper chambers of the heart quiver or flutter instead of contracting correctly, raising the risk of stroke fivefold. Patients are often put on anti-clotting drugs to ward off stroke.

But some people need to temporarily stop taking anti-clotting drugs before surgery or other medical procedures to prevent excess bleeding, while other patients permanently stop taking anti-clotting drugs because of side effects, researchers said.

Researchers analyzed data from a previous trial including more than 14,000 patients with atrial fibrillation. In that trial, rivaroxaban was found to be as effective as warfarin in preventing stroke and blood clots. Both drugs carried about an equal risk of causing excessive bleeding.

In the new study, researchers concentrated on patients who had stopped taking the drugs, either temporarily or permanently. Regardless of which drug was stopped, the rate of strokes and blood clots went up about the same.

Decisions to halt either warfarin or rivaroxaban should be made carefully, since going off the drugs means the heightened stroke risk associated with atrial fibrillation returns, said lead researcher Dr. Manesh Patel, an assistant professor of medicine at Duke University School of Medicine.

"All anticoagulation decisions in patients with atrial fibrillation require risk benefit analysis, and for patients and physicians periods without anticoagulation coverage should be minimized," Patel said.

The study was to be presented Wednesday at the American Heart Association Emerging Science Series.

Atrial fibrillation affects more than 2.3 million men and women in the United States and accounts for more than 15 percent of all strokes, said Dr. Gregg Fonarow, a professor of cardiology at the University of California, Los Angeles. Anticoagulation therapy reduces the risk of stroke by 60 to 80 percent in patients with atrial fibrillation, Fonarow said.

Yet there are key differences between the older and the new drug, including price and how much monitoring is needed, experts said.

Patients taking warfarin need to have the levels of the drug monitored and adjusted regularly to insure it is being effective and not increasing the risk of serious bleeding, while patients taking rivaroxaban don't require as careful monitoring.

"While the newer oral anticoagulants rivaroxaban and dabigatran (Pradaxa) cost approximately $250 a month compared with warfarin, which costs only a few dollars a month, these new agents have the advantage of not requiring monthly blood draws and providing more reliable anticoagulation," Fonarow said.

Because this research has not yet been published, it has not been subjected to the rigorous scrutiny given to research published in peer-reviewed medical journals and should be viewed as preliminary.

The study was partly funded by Johnson & Johnson and Bayer HealthCare AG, which makes rivaroxaban.

More information

The American Heart Association has more on atrial fibrillation.

SOURCES: Manesh Patel, M.D., assistant professor, medicine, Duke University School of Medicine, Durham, N.C.; Gregg Fonarow, M.D., professor, cardiology, University of California, Los Angeles; April 25, 2012, presentation, American Heart Association's Emerging Science Series


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved

Related medicine news :

1. Coaching Boys into Men an effective tool for stopping teen dating violence
2. Stopping hormones might help breast cancer to regress
3. Cell signaling key to stopping growth and migration of brain cancer cells
4. Selectively stopping glutathione sensitizes brain tumors to chemotherapy
5. Hand-Washing Key to Stopping Spread of Disease
6. Some States Make Stopping Smoking Easier Than Others
7. Stopping dangerous cell regrowth reduces risk of further heart attacks
8. Stopping Daily Aspirin Boosts Heart Attack Risk: Study
9. ACP commends Congress for preserving patient access by stopping scheduled Medicare SGR cuts
10. Internists issue heartfelt plea for Congress to help patients by stopping Medicare SGR cuts
11. Researchers find new target for stopping tumors developing their own blood supply
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/2/2016)... ... 02, 2016 , ... MedPro Waste Disposal, LLC (MedPro) is proud to announce ... its mail back service for an all-inclusive rate. MedPro Disposal President, Dan Hansen, says, ... to all of the clients in the country who are looking for an alternative ...
(Date:5/2/2016)... ... 02, 2016 , ... Zitter Health Insights , in ... Award that will recognize specialty pharmacies for their achievements in customer satisfaction. Winners ... Pharmacy Patient Satisfaction Survey compiled throughout 2016. Results will be published in Specialty ...
(Date:5/2/2016)... , ... May 02, 2016 , ... The 2016 World Ultimate & Guts Championship (WUGC) ... at Manhattan College, made the cut. The WUGC is being held in London, England this ... the gold in the men’s division, another gold in the women’s masters division, and a ...
(Date:5/2/2016)... MA (PRWEB) , ... May 02, 2016 , ... Pregnancy ... tips when trying to conceive. , “If you are ready to have ... Mache Seibel. “My book, HealthChequesTM: Journal Babies is your Personal Conception & Pregnancy ...
(Date:5/2/2016)... ... May 02, 2016 , ... ... Permobil, recently completed two groundbreaking studies that determined that the adjustability and adaptability ... critical in the prevention of pressure injuries, which are now referred to as ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... Dr. Vivek Ahuja , ... Ste phen Schmidt ... of cloud-based software solutions for life sciences, today announced key new ... wealth of insight to a growing business.  This will bolster the ... George Phillips joined ArisGlobal in the position of Vice President ...
(Date:4/28/2016)... April 28, 2016 TapImmune,Inc. ... innovative peptide and gene-based immunotherapeutics and vaccines for the treatment ... presenting at the 3rd Annual Growth Capital Expo ... , 2016 at Caesars Palace in Las Vegas, Nevada.  ... Wednesday, May 4 th by Dr. John N. ...
(Date:4/27/2016)... le 27 Avril 2016 ... progressé de +5% sur le trimestre, soutenu par ... consommables  Croissance de +16% des ventes ... Mauna Kea Technologies (Euronext : MKEA, FR0010609263 ; OTCQX : ... laser, annonce aujourd,hui son chiffre d,affaires pour le ...
Breaking Medicine Technology: